Floatz logo

Idarubicine

Lung Non-Small Cell Carcinoma

Second Affiliated Hospital of Guangzhou Medical UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Lung Non-Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
FLUDEOXYGLUCOSE
Alliance for Clinical Trials in Oncology
Phase 3BB
Montanide Isa 51
Roswell Park Cancer Institute
Phase 3BB
Recombinant Human EGF-rP64K
Roswell Park Cancer Institute
Phase 2BB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BB
MITOMYCIN C
City of Hope Medical Center
Phase 3B

View all 24 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →